Iron therapy: Indications, limitations and modality

被引：7

作者：

Arlet, J-B ^{[1
,2
,3
]}

Pouchot, J. ^{[1
]}

Lasocki, S. ^{[4
]}

Beaumont, C. ^{[3
,5
]}

Hermine, O. ^{[3
]}

机构：

[1] Univ Paris 05, Hop Europeen Georges Pompidou, AP HP,Sorbonne Paris Cite, Serv Med Interne,Ctr Reference Syndromes Drepanoc, F-75908 Paris 15, France

[2] CNRS UMR 8147, F-75015 Paris, France

[3] Univ Paris 05, Hop Necker, AP HP,Lab Excellence Globule Rouge GR Ex, Serv Hematol Adulte,Sorbonne Paris Cite, F-75015 Paris, France

[4] Univ Angers, CHU Angers, Inserm 771, UMR CNRS 6214, F-49100 Angers, France

[5] Univ Paris Diderot, Inserm U773, F-75018 Paris, France

来源：

REVUE DE MEDECINE INTERNE | 2013年 / 34卷 / 01期

关键词：

Iron; Erythropoiesis; Hepcidin; Iron deficiency; Anemia of chronic disease; INTRAVENOUS IRON; DOUBLE-BLIND; FERRIC CARBOXYMALTOSE; DEFICIENCY ANEMIA; CONTROLLED-TRIAL; NONANEMIC WOMEN; METABOLISM; PLACEBO; AGENTS; SUPPLEMENTATION;

D O I：

10.1016/j.revmed.2012.04.007

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

During the past 10 years, the knowledge of iron metabolism has been revolutionized by the discovery of the main regulatory hormone of body iron: hepcidin. Meanwhile, new formulations of intravenous iron have been developed and are already or readily available. In this article, we review the recent pathophysiological mechanisms underlying anemia of chronic disease or due to iron deficiency. We describe the various treatment modalities of iron deficiency anemia using oral or intravenous route and the emerging indications of treatment with iron. Finally, we discuss the situations in which iron supplementation may be harmful. (C) 2012 Published by Elsevier Masson SAS on behalf of the Societe nationale francaise de medecine interne (SNFMI).

引用

页码：26 / 31

页数：6

共 38 条

[1] Nonhematological benefits of iron [J].